About Margaret

Professor Margaret Hellard is the Deputy Director (Programs) at the Burnet Institute, Head of Hepatitis Services in the Department of Infectious Disease at The Alfred Hospital and an Adjunct Professor of Infectious Diseases Epidemiology at Monash University in Melbourne, Australia. Margaret’s principal research interests are in preventing the transmission and improving the management of blood borne viruses and sexually transmitted infections, focusing on people who inject drugs (PWID), gay and bisexual men (GBM) and other vulnerable populations.

Margaret is a member of numerous advisory committees and working groups on viral hepatitis and HIV within Australia and globally including being Co-Chair of the WHO Strategic and Technical Advisory Committee on HIV and Viral Hepatitis.  

Margaret is a Principal Investigator of a number of world first studies examining how to increase testing and treatment, and the efficacy hepatitis C treatment as prevention in PWID and  HIV positive gay and bisexual men, using a community settings and social network approaches.  She is undertaking research on how to increase HIV testing and treatment in gay and bisexual men and hepatitis B testing and treatment in culturally and linguistically diverse communities.  She was recently awarded a prestigious NHMRC Program Grant and NHMRC Partnership Grant focusing on hepatitis C elimination projects in Australia and globally. She has over 300 peer reviewed publications and has received over $45 million in competitive research grants and tenders.

This speaker will be presenting at the following session(s)

  • Delivering high quality hepatitis services

    Ballroom 4

    Day: 2 November

    Time: 14:00

    Chair: Liudmyla Maistat, Medicines Patent Pool and Prof. Njoya Oudou, Research Laboratory on Viral Hepatitis and Health Communication

    Presentations:

    • Australia hepatitis service delivery model.
    • Prof. Margaret Hellard, Burnet Institute, The Alfred Hospital and Monash University, Australia
    • HCV testing, treatment and care of people who inject drugs
    • Abigael Lukhwaro, Médecins du Monde
      Sergii Filippovych, Alliance for Public Health
      Prof. David Goldberg, Health Protection Scotland
    • Integrating hepatitis into public health services.
      Prof. Olga Golubovska, Bogomolets National Medical University and Ministry of Health, Ukraine
    • HBV services and indigenous people.
    • Dr. Brian McMahon, Alaska Native Tribal Health Consortium
    • Q & A session.

    Session objectives:

    • Review examples of service delivery models for different population groups.
    • Discuss gaps in HBV vaccination, HBV and HCV testing, diagnosis, treatment and care cascade for key populations in different settings and possible solutions to filling in the gaps.
    • Assess the role of case management; peer-to-peer support in community-based or community oriented service delivery.